Zobrazeno 1 - 10
of 34
pro vyhledávání: '"Peter L.J. Wijngaard"'
Autor:
Herman J. Kempen, Monica Gomaraschi, S. Eralp Bellibas, Stephanie Plassmann, Brad Zerler, Heidi L. Collins, Steven J. Adelman, Laura Calabresi, Peter L.J. Wijngaard
Publikováno v:
Journal of Lipid Research, Vol 54, Iss 9, Pp 2341-2353 (2013)
MDCO-216, a complex of dimeric recombinant apoA-IMilano (apoA-IM) and palmitoyl-oleoyl-phosphatidylcholine (POPC), was administered to cynomolgus monkeys at 30, 100, and 300 mg/kg every other day for a total of 21 infusions, and effects on lipids, (a
Externí odkaz:
https://doaj.org/article/0b9d762da57a455d801257a98cd6cd14
Autor:
Robert M. Stoekenbroek, Arash Haghikia, Ulf Landmesser, Lawrence A. Leiter, Kausik K. Ray, Peter L.J. Wijngaard, John J.P. Kastelein, R. Scott Wright, David Kallend
Publikováno v:
Cardiovascular research, 117(1), 284-291. Oxford University Press
Aims Small-interfering RNA (siRNA)-based targeting of proprotein convertase subtilisin/kexin type 9 (PCSK9) represents a novel therapeutic approach that may provide a convenient, infrequent, and safe dosing schedule to robustly lower low-density lipo
Publikováno v:
Toxicology and Applied Pharmacology. 451:116144
Autor:
Robert M. Stoekenbroek, Norman E. Lepor, Frederick J. Raal, Peter L.J. Wijngaard, G. Kees Hovingh, David Kallend
Publikováno v:
Circulation, 141(22), 1829-1831. Lippincott Williams and Wilkins
Publikováno v:
Toxicology and Applied Pharmacology. 443:115978
Autor:
R.S. Wright, Wolfgang Koenig, Peter L.J. Wijngaard, David Kallend, Lawrence A. Leiter, Frederick J. Raal, John J.P. Kastelein, Ulf Landmesser, Robert M. Stoekenbroek, G.G Schwartz, Kausik K. Ray
Publikováno v:
European Heart Journal. 41
Introduction Inclisiran, an investigational siRNA, has been shown to effectively and durably lower LDL-C in Phase 3 trials. Inter-individual variability in LDL-C reductions has been documented for statin therapy and ezetimibe. Purpose To evaluate the
Pooled safety and efficacy of inclisiran in patients with statin intolerance (ORION-10 and ORION-11)
Autor:
John J.P. Kastelein, R.S. Wright, L A Leiter, Peter L.J. Wijngaard, Wolfgang Koenig, David Kallend, Ulf Landmesser, Frederick J. Raal, Robert M. Stoekenbroek, G.G Schwartz, Kausik K. Ray
Publikováno v:
European Heart Journal. 41
Introduction Statin-associated side effects prevent a substantial proportion of patients from being adequately treated with statin therapy and achieving adequate LDL-C reductions. Phase 3 trials showed that inclisiran, a new siRNA, durably lowers LDL
Autor:
Traci Turner, Wolfgang Koenig, David Kallend, Frederick J. Raal, Danielle Curcio, Lawrence A. Leiter, John J.P. Kastelein, R. Scott Wright, Peter L.J. Wijngaard, Mark Jaros, Kausik K. Ray
Publikováno v:
New England journal of medicine, 382(16), 1520-1530. Massachussetts Medical Society
Background: \ud Familial hypercholesterolemia is characterized by an elevated level of low-density lipoprotein (LDL) cholesterol and an increased risk of premature atherosclerotic cardiovascular disease. Monoclonal antibodies directed against proprot
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::330f9657545bdd896d53442326c2a483
https://pure.amc.nl/en/publications/inclisiran-for-the-treatment-of-heterozygous-familial-hypercholesterolemia(f271f5cc-0cb5-414b-93c6-b770f2514198).html
https://pure.amc.nl/en/publications/inclisiran-for-the-treatment-of-heterozygous-familial-hypercholesterolemia(f271f5cc-0cb5-414b-93c6-b770f2514198).html
Autor:
Peter L.J. Wijngaard, Wolfgang Koenig, David Kallend, R. Scott Wright, John J.P. Kastelein, Tara Richardson, Lawrence A. Leiter, Kausik K. Ray, Frederick J. Raal, Mark Jaros, Jenna A. Bisch
Publikováno v:
New England journal of medicine, 382(16), 1507-1519. Massachussetts Medical Society
Background: \ud Inclisiran inhibits hepatic synthesis of proprotein convertase subtilisin–kexin type 9. Previous studies suggest that inclisiran might provide sustained reductions in low-density lipoprotein (LDL) cholesterol levels with infrequent
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fb98da7be0267e96d0620d704f9eec88
http://hdl.handle.net/11573/1466248
http://hdl.handle.net/11573/1466248
Autor:
Richard A. Robson, Peter L.J. Wijngaard, R. Scott Wright, Lawrence A. Leiter, David Kallend, Michael G. Collins, John J.P. Kastelein, Kausik K. Ray, Ulf Landmesser, Robert M. Stoekenbroek
Publikováno v:
Mayo Clinic proceedings. Mayo Clinic, 95(1), 77-89. Elsevier Science
Objective: To investigate the pharmacodynamic properties of inclisiran, a small interfering RNA targeting proprotein convertase subtilisin-kexin type 9 (PCSK9), in individuals with normal renal function and renal impairment (RI). Patients and Methods
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1d84fa4f8b1eb4cb78e427f52931690a
https://pure.amc.nl/en/publications/effects-of-renal-impairment-on-the-pharmacokinetics-efficacy-and-safety-of-inclisiran-an-analysis-of-the-orion7-and-orion1-studies(ddc1d0cc-59fd-42c3-9b1a-d9ddf46a317c).html
https://pure.amc.nl/en/publications/effects-of-renal-impairment-on-the-pharmacokinetics-efficacy-and-safety-of-inclisiran-an-analysis-of-the-orion7-and-orion1-studies(ddc1d0cc-59fd-42c3-9b1a-d9ddf46a317c).html